[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371208-105":3,"detail-sidebar-cat-0-en-105":77,"doc-detail-371208-en":126},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":70,"head_meta":72,"extra_data":74,"updated_unix":76},105,"en","linking-tumor-immune-infiltration-to-enhanced-longevity-in-recurrence-free-breast-cancer","Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer","","Infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer relates to lower distant metastasis risk, yet the effect of B-cell tumor infiltration on overall survival was uncertain. This study analyzed 9638 breast cancer patients across three datasets, using a 14-gene B-cell/immunoglobulin (IGG) signature to estimate mortality risk. IGG characterization combined spatial GeoMx profiling with single-cell RNA sequencing, and evaluated links to tertiary lymphoid structures (TLSs) and immune clonality.",{"@graph":14,"@context":69},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/linking-tumor-immune-infiltration-to-enhanced-longevity-in-recurrence-free-breast-cancer/371208/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/linking-tumor-immune-infiltration-to-enhanced-longevity-in-recurrence-free-breast-cancer/371208.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65],{"name":60,"@type":61,"acceptedAnswer":62},"How was the IGG signature measured and characterized?","Question",{"text":63,"@type":64},"The IGG signature was measured using profiling approaches including spatial GeoMx profiling and single-cell RNA sequencing, followed by assessment of relationships with B- and T-cell clonality and tertiary lymphoid structures (TLSs).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the results show about longevity and relapse-free survival?",{"text":68,"@type":64},"High IGG signature expression was associated with a 41%–47% reduction in death risk among breast cancer survivors. In breast cancer patients aged 41–70 at diagnosis, the IGG signature also linked to overall survival without relapse, with additional correlations to TLS presence and higher B- and T-cell polyclonality.","https://schema.org",{"og:url":32,"og:type":71,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":73,"canonical":32},"index,follow",{"doc_id":75,"site_id":7},371208,1790362628,{"code":4,"msg":78,"data":79},"success",[80,84,88,92,97,102,106,110,115,118,122],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Exam",70,"exam",{"id":93,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},5,"Comic",60,"comic",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},6,"Technology",50,"technology",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Research & Report",30,"research-report",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},9,"Religion & Spirituality",20,"religion-spirituality",{"id":113,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":113,"slug":117},"World Cup","world-cup",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":119,"slug":121},10,"Lifestyle","lifestyle",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":93,"slug":125},19,"General","general",{"code":4,"msg":78,"data":127},{"doc_id":75,"user_id":128,"nickname":42,"user_avatar":129,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":135,"language":136,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":12,"update_tm":140,"read_time":141},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nLinking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer  \nL. Angelats1, 2 , 3y, L. Paré4y, C. Rubio-Perez1, 2y, E. Sanfeliu1, 5, A. González5, 6, E. Seguí1, 2, G. Villacampa7, M. Marín-Aguilera4,  \nS. Pernas8, 9, B. Conte1, 2, V. Albarrán-Fernández1, 2, O. Martínez-Sáez1, 2, 3, Á . Aguirre1, 2, P. Galván1, 2, 4,  \nA. Fernandez-Martinez10, S. Cobo1 , 2, M. Rey1 , 2, A. Martínez-Romero1, 2, B. Walbaum1, 2, F. Schettini1, 2, M. Vidal1, 2,  \nW. Buckingham4, M. Muñoz1, 2, B. Adamo1, 2, Y. Agrawal11, S. Guedan12, T. Pascual1, 2, 3, 13, J. Agudo14, 15 , 16, 17,  \nM. Grzelak18, N. Borcherding18, H. Heyn18, A. Vivancos19, J. S. Parker11, P. Villagrasa4, C. M. Perou10, 11,  \nA. Prat1, 2, 3, 4, 20z & F. Brasó-Maristany1, 2, 4􀀂z  \n1Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; 2Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona; 3Department of Medicine, University of Barcelona, Barcelona; 4Reveal Genomics, Barcelona; 5Department of Pathology, Hospital Clinic of Barcelona, Barcelona; 6Immunogenetics and Immunotherapy in Autoinflammatory and Immune Responses, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; 7Statistics Unit, Vall d’Hebron Institute of Oncology, Barcelona; 8Institut Catala d’Oncologia, IDIBELL, L’Hospitalet de Llobregat, Barcelona; 9Institut Català d’Oncologia Medical Oncology, Breast Unit Barcelona, Barcelona, Spain; 10Department of Genetics, University of North Carolina, Chapel Hill; 11Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA; 12Cellular Immunotherapies for Cancer Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; 13SOLTI Cancer Cooperative Group, Barcelona, Spain; 14Department of Cancer Immunology and Virology, DanaFarber Cancer Institute, Boston; 15Department of Immunology, Harvard Medical School, Boston; 16Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston; 17New York Stem Cell Foundation, Robertson Investigator, New York; 18Omniscope Inc., Palo Alto, USA; 19Vall d’Hebron Institute of Oncology (VHIO), Cancer Genomics Group, Barcelona; 20Institute of Oncology (IOB)dHospital Quirónsalud, Barcelona, Spain  \nAvailable online xxx  \nBackground: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.  \nMaterials and methods: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets. Associations with tumor subtype, stage, and age were examined. IGG was characterized using spatial GeoMx profiling and single-cell RNA sequencing, and its relationship with tertiary lymphoid structures (TLSs) was evaluated. The predictive value of each of the 14 IGG genes for B-cell receptor (BCR) and T-cell receptor (TCR) clonality and longevity was also assessed, along with its association with longevity in other cancer types.  \nResults: High IGG signature expression was significantly associated with a 41%-47% reduction in death risk in breast cancer survivors (P \u003C 0.001), regardless of age, tumor stage, or subtype. Similar associations were observed in other cancers, including melanoma. In breast cancer, the IGG signature was significantly linked to overall survival without relapse in patients aged 41-70 years at diagnosis. Additionally, IGG expression correlated with the presence of TLSs and higher B- and T-cell polyclonality. A specific subset of seven IGG genes strongly correlated with BCR and TCR clonality, with predictive power for identifying clonality and improved longevity, especially when combining two of these","cbCaip36UOD5YbtG","https://ap.wps.com/l/cbCaip36UOD5YbtG","pdf",2087079,11,"English","# Introduction\n# Materials and methods\n# Results\n# Conclusions\n# Key words","[{\"question\":\"How was the IGG signature measured and characterized?\",\"answer\":\"The IGG signature was measured using profiling approaches including spatial GeoMx profiling and single-cell RNA sequencing, followed by assessment of relationships with B- and T-cell clonality and tertiary lymphoid structures (TLSs).\"},{\"question\":\"What did the results show about longevity and relapse-free survival?\",\"answer\":\"High IGG signature expression was associated with a 41%–47% reduction in death risk among breast cancer survivors. In breast cancer patients aged 41–70 at diagnosis, the IGG signature also linked to overall survival without relapse, with additional correlations to TLS presence and higher B- and T-cell polyclonality.\"}]","Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer | PDF",1790191521,28]